Cristina Magi-Galluzzi, MD, PhD, discussed the role of pathologists in the diagnosis and treatment decision for patients with prostate, bladder, and renal cancers.
In an interview with Targeted Oncology, John Bartlett, MD, explained the standardized cancer testing project, its relevance, and how it could be used to improve the treatment of patients with pancreatic, prostate, breast cancer.
Corey J. Langer, MD, detailed the best courses of treatment for a patient with non–small cell lung cancer to a group of physicians during a recent Targeted Oncology live case-based peer perspectives discussion.
In an interview with <em>Targeted Oncology</em>, Naveen Pemmaraju, MD, discussed the results from the phase I/II trial of single-agent tagraxofusp used to treat patients with R/R myelofibrosis and examined novel agents and combination regimens that are being studied to potentially treat this patient population.<br /> <br />
In an interview with <em>Targeted Oncology</em>, Gregorz S. Nowakowski, MD explained the details of the ECOG-ARIN 1412 trial and how the positive results related to patients with DLBCL will further improve outcomes for patients with all lymphoma types.
In an interview with <em>Targeted Oncology</em>, Michael Atkins, MD, discussed the latest follow-up data from the combination of nivolumab and ipilimumab across 2 trials and next steps in the research with this combination for patients with advanced melanoma.
In an interview with <em>Targeted Oncology</em>, Shilpa Gupta, MD, discussed the results of the phase I/Ib trial of enzalutamide and gemcitabine and cisplatin in metastatic bladder cancer and defining platinum ineligibility in patients with metastatic urothelial cancer.
In an interview with <em>Targeted Oncology,</em> Carol Mangione, MD, MSPH, a co-author on the USPSTF Recommendation Statement, gave insight into the specifics of the recommendations and how the Task Force hopes these suggestions will impact patient outcomes.<br />
In an interview with <em>Targeted Oncology</em>, McCloskey discussed current treatment options for patients with myelofibrosis as well as further options in development in clinical trials. McCloskey recommended that community oncologists partner with specialists to improve the prognosis for these patients until new agents are approved, and for referrals to clinical trials for further research for this patient population.
During the <em>20th Annual </em>International Lung Cancer Congress, <em>Targeted Oncology</em> spoke with another Lung-MAP investigator, Fred R. Hirsch, MD, PhD, about the status and importance of the trial and new recommendations for molecular testing and liquid biopsies working their way into practice in the lung cancer field.
In an interview with <em>Targeted Oncology</em>, Agarwal, professor of medicine at the Huntsman Cancer Institute, University of Utah, gave an overview of the TALAPRO-2 trial and discussed its potential for changing the standard of care for patients with mCRPC.
Heather Williams, MD provided background on the study of nivolumab as salvage therapy in heavily pretreated patients with gynecologic malignancies in an interview with <em>Targeted Oncology</em>.<strong> </strong>
In an interview with <em>Targeted Oncology</em> following his presentation at the <em>3rd Annual</em> Congress on Oncology & Pathology hosted by PER®, Gulam A. Manji, MD, discussed the emergence of new therapies for targeting mutations in patients with colon cancer.
In an interview with <em>Targeted Oncology </em>following a presentation at the Charlotte Plasma Cell Disorder Congress, Cesar Rodriguez Valdes, MD explained how small molecules fit into the myeloma treatment and notes the ongoing research that shows promise for the next class of small molecules in the future.<br />
In an interview with <em>Targeted Oncology, </em>James McCloskey, MD, explained the need for consideration of elderly patients when designing clinical trials for <em>IDH</em>-mutated AML and other considerations when treating this patient population.
During an interview with <em>Targeted Oncology</em>, Charu Agarwal, MD, reviewed the findings of a prospective study of pembrolizumab monotherapy in patients with advanced NSCLC.
Reporting on the debate with his peer, Lawrence J. Solin, MD, FACR, FASTRO explained his stance on whole breast irradiation in comparison with partial breast irradiation in breast cancer treatment during an interview with <em>Targeted Oncology</em>. More research is needed to support the idea that PBI can be used for more patients, according to Solin.
In an interview with <em>Targeted Oncology</em>, Llovet discussed the positive results from the REACH-2 trial and how its results are shaping future combinations therapies for the treatment of patients with advanced HCC.
Mark J. Ratain, MD provided guidance on the current landscape for research biopsies in clinical trials and talked through the recommendations and how the new ethical framework can improve clinical trials during an interview with <em>Targeted Oncology</em>. He also explained the potential role for liquid biopsies and blood-based biomarker testing within clinical research.
In the phase I/II TRANSCEND CLL 004 study, chimeric antigen receptor T-cell therapy lisocabtagene maraleucel led to undetectable minimal residual disease in patients with relapsed/refractory chronic lymphocytic leukemia.
In an interview with <em>Targeted Oncology</em>, Kieron Dunleavy, MD, examined the role of liquid biopsy throughout the course of disease for all lymphomas, and specifically for patients with mantle cell lymphoma, and how its role may change in the future.
Kieron Dunleavy, MD, discussed current approaches to treating patients with MCL, highlighting peer discussions on the subject and information about the ZUMA-2 trial, in an interview with <em>Targeted Oncology</em>.
During an interview with <em>Targeted Oncology</em>, Aditya Bardia, MD, MPH, discussed the current role of both liquid biopsy and NGS in breast cancer management, improvements that are needed, and research that shows a promising future.
In an interview with <em>Targeted Oncology</em>, Peter Martin, MD, assistant professor of medicine, Division of Hematology/Oncology, Weil Cornell Medicine, recounts physician crossfire discussions related to frontline MCL treatment and provides his own expert opinion on the subject.
During an interview with <em>Targeted Oncology</em>, Guru P. Sonpavde, MD highlights the extensive research around checkpoint inhibition and chemotherapy combinations and how these regimens are advancing bladder cancer treatment.
Over the past 2 years, the amount of FDA-approved frontline treatments for patients with acute myeloid leukemia have increased. These emergent treatments have caused a shift in the standard of care for patients with AML and inspiring analyses of regimens that researchers believe can improve outcomes for AML treatment.
Testosterone suppression with docetaxel, the standard of care for patients with metastatic hormone-sensitive prostate cancer (mHSPC), was combined with chemotherapy or enzalutamide (Xtandi) to assess the potential improvement in overall survival compared with non-steroidal anti-androgens like bicalutamide, nilutamide, and flutamide in the phase III ENZAMET trial. <br />
The combination of erlotinib and ramucirumab showed better progression-free survival in patients with newly diagnosed <em>EGFR</em>-mutant metastatic non–small cell lung cancer compared with erlotinib plus placebo, based on findings from the RELAY trial presented during the 2019 ASCO Annual Meeting.
A single-arm, multicenter phase II trial held in China analyzed the Bruton’s tyrosine kinase inhibitor zanubrutinib for treatment of patients with relapsed/refractory mantle cell lymphoma. Previously, the investigational BTK inhibitor gained a breakthrough designation from the FDA based on early results from the phase II trial that showed zanubrutinib to be highly active.<br />
The Association of Community Cancer Centers has launched the Barriers to Quality Care in Ovarian Cancer project, a collaboration with AstraZeneca, Merck, and partners including the Association for Molecular Pathology, the National Society of Genetic Counselors, and the Society of Gynecologic Oncology. The project aims to understand the key issues associated with ovarian cancer care and provide guidance to help cancer centers implement better care for patients diagnosed with epithelial ovarian cancer.